BusinessJul 16, 2026
Healthcare Is Finding a New Balance. Not Every Business Is Keeping Up
Sector Rotations
Rhea Lobo
Discover
Healthcare stocks are flashing a split signal this earnings season. Insurers are beating estimates by cutting costs and hiking premiums, but they're shedding members at a steady clip. Meanwhile, medical device and diagnostics companies are posting stronger numbers.
UnitedHealth Group blew past Q2 estimates, raising its full-year adjusted earnings outlook to $19.50-$20.00 per share from a prior floor of $18.25. Revenue came in at $112B.
"These results are not a reflection of trend bending or coming under control, but rather our efforts to start pushing down what is already an elevated number."
Wayne DeVeydt, UnitedHealth Group
UnitedHealth's medical benefit ratio, which measures the share of premiums paid out as medical claims, dropped to 86.7% from 89.4% a year earlier. Analysts had expected 88.5%. A lower ratio means the company kept more of every premium dollar.
The company is investing $1.5B in artificial intelligence to speed up prior authorizations and detect billing fraud. DeVeydt said AI tools are not approving or denying care directly.
The improvement in profitability is coming at a cost. UnitedHealth served 48.5M people in Q2, down 525,000 from the prior quarter.
The company expects to lose roughly 500K ACA exchange members and 1.1M Medicare Advantage members for the full year.
Elevance Health told a similar story. The insurer reported membership fell sequentially by 469K to 44.9M as of end of June. Medicare Advantage membership dropped 15.9% while Medicaid enrollment fell 4.3%.
Elevance still beat estimates. The company raised its full-year adjusted earnings outlook to at least $27 per share.
But Elevance shares fell on the membership figures. Higher premiums, with some ACA plan rates rising as much as 24% this year, are keeping revenue stable while enrollment shrinks. The company has requested hikes as high as 17% for 2027.
The benefit-expense ratio at Elevance rose to 89.7% from 88.9% a year earlier. Both companies attribute membership pressure to affordability strains driven by higher medical costs and reduced federal subsidies.
The membership losses insurers are reporting translate into uninsured patients for hospitals. HCA Healthcare cut its full-year guidance after flagging a payer mix shift driven by an increase in uninsured volume.
The company estimates this shift had an unfavorable pretax income impact of ~$400M in Q2 alone. HCA now expects full-year earnings of $28.70 to $30.50 per share, down from its prior range. Shares had already fallen 22% in the three months before the guidance cut.
As ACA exchange enrollment declines, some patients show up to hospitals without coverage. Hospitals then absorb costs they cannot fully recover. That pressure flows directly from the insurer membership data.
Abbott Laboratories offered a different read on the sector. The company raised its annual profit forecast to $5.45 to $5.60 per share after beating Q2 estimates. Diagnostics segment sales grew 42% while medical devices sales grew 9%.
Abbott CEO Robert Ford directly addressed hospital volume concerns flagged by HCA, calling it a flawed assumption that ACA enrollment declines would materially affect medtech and diagnostics.
He argued that the company's exposure to chronic conditions like diabetes, cardiovascular disease, and cancer makes those patients less likely to drop coverage entirely.
Boston Scientific, Stryker, and Medtronic each rose ~5% in morning trading on the day of Abbott's report. Johnson & Johnson also raised its full-year guidance after a stronger-than-expected quarter driven by its oncology portfolio.
The pattern across this earnings week is clear. Healthcare earnings are revealing a new pecking order as insurers stabilize, hospitals absorb the pressure, and medtech keeps delivering.
